Bionik Laboratories Corp.: insider trades · United States · SEC (Form 4)

About Bionik Laboratories Corp.

Bionik Laboratories Corp. is a medical robotics company focused on neurorehabilitation and mobility solutions. For French-speaking investors, the key framing is that the company operates in the U.S. capital-markets ecosystem through SEC reporting and insider Form 4 filings, even though its operational heritage is rooted in North American healthcare technology. Its profile sits squarely in the healthcare technology and rehabilitation robotics niche, with exposure to the public U.S. market and a historically international footprint. Founded in the early 2010s, Bionik built its platform around technologies that draw on biomechanics and neurorehabilitation research, including work associated with MIT’s Newman Laboratory. The company states it was incorporated in 2010 and later expanded through the acquisition of Interactive Motion Technologies, which strengthened its portfolio across upper- and lower-extremity rehabilitation. Over time, the business has also gone through restructuring phases, which is an important consideration for investors assessing commercialization execution, balance-sheet resilience, and the company’s ability to convert clinical credibility into durable revenue. Bionik’s core business is centered on the InMotion® line of robotic therapy systems for patients with neurological impairment, particularly stroke recovery and related conditions. The marketed portfolio includes InMotion ARM™, InMotion WRIST™, InMotion HAND™, and InMotion ANKLE™, alongside development programs such as ARKE™, a lower-body mobility and rehabilitation exoskeleton concept. The company positions its products as patient-adaptive systems that combine repetition, real-time feedback, and data capture to help clinicians tailor therapy and track progress. From a competitive standpoint, Bionik occupies a specialized niche within robotic rehabilitation, competing against broader medical device and rehabilitation technology players rather than mass-market healthcare companies. Its potential differentiators are the clinical evidence base, the emphasis on data-driven therapy, and the modular nature of its rehabilitation platform. Bionik highlights a substantial body of independent clinical research and peer-reviewed publications supporting the use of its devices, which helps reinforce its medical-technology positioning. Geographically, the company is transnational: it has historical roots in Toronto, Canada, and operational presence in the United States, including Massachusetts. That matters for investors because the commercial opportunity is tied to the U.S. rehabilitation market, while the corporate structure and execution history have been shaped by a smaller, cross-border operating footprint. Recent company messaging continues to emphasize product commercialization, ongoing development projects, and a rehabilitation model built around robotics and analytics. For market participants following SEC insider activity, Form 4 filings are worth monitoring as potential indicators of governance developments, ownership changes, or sentiment around the stock. Importantly, Bionik Laboratories Corp. is not presented here as a NYSE or NASDAQ listed issuer; its current public-market presence is associated with OTCQB trading, so investors should treat liquidity and disclosure depth accordingly.